PHASE II SINGLE-CENTER, RANDOMIZED, OPEN-LABEL, PROSPECTIVE, STUDY TO DETERMINE THE IMPACT OF SERIAL PROCALCITONIN

NCT04983901 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

100

Enrollment

OTHER

Sponsor class

Conditions

Hematopoietic and Lymphoid Cell Neoplasm
Malignant Solid Neoplasm

Interventions

DRUG: Imipenem/Cilastatin/Relebactam
DRUG: Cefepime
DRUG: Meropenem
DRUG: Piperacillin-Tazobactam
DRUG: Vancomycin
DRUG: Daptomycin
DRUG: Linezolid

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]